GlassScriptPhysician profile
Edward Merker
NPI 1356447064
$1,653.58
in general payments reported to CMS, 2019-2025
14 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $182 · 2022: $18.61 · 2024: $157 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $386.32 | 2019-2020 | |
| Mannkind Corporation | $330.80 | 2019 | |
| Ascendis Pharma Endocrinology INC | $172.79 | 2025 | Yorvipath |
| Novo Nordisk INC | $157.60 | 2020-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $124.99 | 2020 | |
| Sanofi-Aventis U.S. LLC | $100.05 | 2019 | |
| Amgen INC. | $90.86 | 2022-2025 | Repatha, Repatha, Evenity |
| Chiesi USA, INC. | $89.56 | 2024-2025 | Mycapssa |
| Abbvie INC. | $59.49 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.25 | 2025 | |
| Madrigal Pharmaceuticals | $31.97 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $29.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.67 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Merker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.